Sontuzumab Biosimilar – Anti-MUC1, CD227 mAb – Research Grade from ProteoGenix; catalogue PX-TA1179; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Sontuzumab Biosimilar, also known as Anti-MUC1 or CD227 mAb, is a monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody Sontuzumab. This antibody specifically targets the MUC1 protein, which is overexpressed in many types of cancer, making it a promising therapeutic target for cancer treatment. In this article, we will discuss the structure, activity, and potential applications of Sontuzumab Biosimilar in research.
Sontuzumab Biosimilar is a humanized monoclonal antibody, meaning it is derived from both human and non-human sources. It is composed of two identical heavy chains and two identical light chains, each containing a variable region and a constant region. The variable region is responsible for binding to the MUC1 protein, while the constant region determines the antibody’s effector functions.
Sontuzumab Biosimilar binds to the extracellular domain of the MUC1 protein, which is overexpressed on the surface of cancer cells. This binding inhibits the growth and survival of cancer cells by blocking the interaction between MUC1 and other cell receptors, as well as inducing antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). In addition, Sontuzumab Biosimilar has been shown to enhance the anti-tumor immune response by activating natural killer cells and T cells.
Sontuzumab Biosimilar has been primarily developed for use in cancer research, specifically in the treatment of solid tumors. It has shown promising results in preclinical studies, demonstrating its ability to inhibit tumor growth and improve survival in animal models. Additionally, Sontuzumab Biosimilar has been shown to enhance the efficacy of chemotherapy and radiation therapy when used in combination.
Furthermore, Sontuzumab Biosimilar has potential applications in the diagnosis and imaging of cancer. MUC1 is not only overexpressed on the surface of cancer cells, but it is also shed into the bloodstream. This makes it a potential biomarker for cancer detection and monitoring. Sontuzumab Biosimilar can be labeled with a radioactive tracer or fluorescent dye, allowing for the visualization of MUC1-positive tumors in imaging techniques such as positron emission tomography (PET) or fluorescence imaging.
In summary, Sontuzumab Biosimilar is a promising therapeutic antibody that specifically targets the MUC1 protein, which is overexpressed in many types of cancer. Its unique structure and activity make it a valuable tool in cancer research, with potential applications in both treatment and diagnosis. Further studies and clinical trials are needed to fully explore the potential of Sontuzumab Biosimilar in the fight against cancer.
ProteoGenix catalogue number PX-TA1179. For research use only.
Target: Sontuzumab Biosimilar – Anti-MUC1, CD227 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Sontuzumab Biosimilar – Anti-MUC1, CD227 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
